Synchronizing
The Power Of
Immunotherapy
Syncromune® is developing SYNC-T™, an in situ personalized platform therapy that combines partial tumor oncolysis and a multi-target biologic drug designed to empower the immune system to recognize and attack cancer
®
SYNC-T™ In Situ Combination Multi-Target Cancer Therapy
The SYNC-T solid tumor therapy platform is personalized and performed in situ (within the body). It is a first-in-class therapy that uniquely combines partial oncolysis of a tumor with infusion of a multi-target biologic drug directly into the tumor. This method is designed to simultaneously address numerous immune suppression mechanisms while also being immunostimulatory. The synergistic approach can lead to T cell activation and proliferation. Patient-specific T cells can then migrate and attack tumors systemically throughout the body.
SYNC-T Animation: How it Works
Syncromune® is at the forefront of developing personalized immunotherapies designed to help patients with advanced cancer. Our desire to develop solutions for patients with unmet needs drives us every day.
If you would like more information about our clinical trials, please click below.
Disclaimers: The content on this website is intended for healthcare professionals. The compounds and their uses mentioned on this website are investigational and have not been determined safe and effective by the relevant regulatory authorities, including the US Food and Drug Administration or other applicable agencies in other countries.
